PCN9 COST-EFFECTIVENESS OF SUPERFICIAL BLADDER CANCER SURVEILLANCE IN WHICH CYSTOSCOPY IS PARTLY REPLACED BY MICROSATELLITE ANALYSIS  by De Bekker-Grob, EW et al.
PCN7
PRIMARY PROPHYLAXIS AGAINST FEBRILE NEUTROPENIA
WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH
FILGRASTIM IN NON-HODGKIN’S LYMPHOMA PATIENTS
RECEIVING CHOP-21 IN SPAIN
Lopez A1,Arocho R2,Atchison C3, Malin JL4, Liu Z5, Doan QV5,
Dubois RW5
1Vall d’Hebron University Hospital, Barcelona, Spain, 2Amgen SA,
Barcelona, Spain, 3Amgen (Europe) Gmbh, Zug, Switzerland, 4Amgen
Inc,Thousand Oaks, CA, USA, 5Cerner Corporation, Beverly Hills,
CA, USA
OBJECTIVES: Primary prophylaxis with granulocyte-colony
stimulating factors, used in the ﬁrst and subsequent cycles of
chemotherapy, is recommended by the 2006 ASCO and EORTC
clinical guidelines when the overall risk of febrile neutropenia
(FN) is 20%. Pegﬁlgrastim effectively reduces the risk of FN
with a single injection per cycle compared with 11 injections on
average for ﬁlgrastim as observed in clinical trials. The study
objective was to evaluate the cost-effectiveness of primary pro-
phylaxis with pegﬁlgrastim versus ﬁlgrastim in patients with
aggressive non-Hodgkin’s lymphoma (NHL) receiving CHOP-21
chemotherapy in Spain. METHODS: A decision-analytic model
was constructed from a health care payer’s perspective with a
life-time model horizon. Costs (2006 value) including drugs,
drug administration, FN-related hospitalisations, and medical
costs subsequent to FN hospitalisations were acquired from ofﬁ-
cial price lists or literature. Other model inputs including FN
risk, FN case-fatality, relative dose intensity (RDI), the impact of
RDI on survival, and health utilities were based on data from a
comprehensive literature review and expert panel validation.
Using data from a meta-analysis, we estimated that the absolute
risk of FN in patients receiving pegﬁlgrastim decreased
from 19.6% to 13.1% (6.5 percentage points) versus 11-day
ﬁlgrastim. NHL mortality and all-cause mortality were obtained
from ofﬁcial statistics. Sensitivity analyses were performed on
key parameters. RESULTS: The incremental cost-effectiveness
ratio (ICER) was €185 per FN event avoided or €2 per 1%
decrease in absolute risk of FN. Pegﬁlgrastim achieved 0.06 more
discounted life-years or 0.053 more discounted quality-adjusted
life-years (QALY) at a minimal cost increase of €12 per person
(€6550 versus €6538), yielding an ICER of €195/LYG and €218/
QALY saved. Results were most sensitive to the relative risk of
FN for 11-day ﬁlgrastim versus pegﬁlgrastim. CONCLUSION:
In Spain, pegﬁlgrastim was cost-effective compared with 11-day
ﬁlgrastim in NHL patients using CHOP-21.
PCN8
A COST-CONSEQUENCE ANALYSIS OF DARBEPOETIN ALFA
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OBJECTIVE: Anemia, a common chemotherapy complication,
is often treated with erythropoiesis-stimulating agents (ESAs).
The objective of this study was to assess, based on the results
of a European retrospective observational study, the cost con-
sequence of Q3W_DA administration (500 mg) compared to
QW_EA or QW_EB at the European label doses, from an
Italian healthcare perspective. METHOD: A decision-tree
model making explicit the conduct of the patients in the
16-week observational study (drug administrations, transfusion
and response to treatment) was developed in MSExcel. Transi-
tion probabilities, average hemoglobin value over treatment
period and number of blood transfusions were extracted from
the observational study. Unit costs were applied to medical
resources used (red blood cells packs, healthcare professional
visits, hospital stays, diagnostic tests). These resources as well
as the probabilities of a drug being administered in different
settings were estimated according to consultations with Italian
oncologists. Medical costs were extracted from ofﬁcial sources
(Tariffari, Ministero della Salute) and adjusted to 2007€. A
5000-replications probabilistic sensitivity analysis was per-
formed with @RISK® using distributions for probabilities
(binomial), medical resources used (triangular) and outcome
measures (normal). RESULTS: Between treatment groups,
hemoglobin differences were: Q3W_DA minus QW_EA,
0.13g/dL (95%CI: -0.152; 0.415) and Q3W_DA minus
QW_EB, 0.19g/dL (95%CI: -0.0117; 0.385). The cost was
lower compared to QW_EA (-310€ [95%CI: -620; -9]) and
slightly higher compared to QW_EB (84€ [95%CI: -113;
269]). Probabilistic sensitivity analysis revealed for Q3W_DA
80% of the replications vs. QW_EA and 18% vs. QW_EB with
better hemoglobin values and lower costs (dominant); 2% vs.
QW_EA and 79% vs. QW_EB with slightly higher costs and
better hemoglobin values. CONCLUSION: This analysis pro-
vides real-life information to decision makers about the costs
and consequences of Q3W_DA compared to QW_EA and
QW_EB. A decision in favor of Q3W_DA has the highest prob-
ability to be beneﬁcial from the Italian healthcare perspective.
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OBJECTIVES: To assess the cost-effectiveness of a surveillance
strategy in which cystoscopy is partly replaced by microsatellite
analysis (MA) to identify loss of heterozygosity (LOH) in urine
samples versus conventional cystoscopy-based surveillance in
patients treated for superﬁcial bladder cancer. METHODS: A
semi-Markov model was used, which was implemented in
TreeAge Software. Data from the randomised study (n = 448)
and literature were used. The reference case was a man aged 65,
and the time horizon was two years. A societal perspective was
adopted. Sensitivity analyses were performed to evaluate the
effects of varying costs and effects. RESULTS: The sensitivity of
MA was 0.56 (cystoscopy 0.95), which was too low to compen-
sate for the ability to detect recurrent tumors in the upper urinary
tract (which are missed by cystoscopy). The MA test also had
worse speciﬁcity than cystoscopy (0.74 vs. 0.97). The control
arm hence led to better outcomes than the test arm, and lower
costs (€2691 vs €3785 per capita over the course of two years).
Although the Markov model indicated that the control arm
dominated the test arm, patient preferences for the urinary test
may be strong, accepting a slightly worse medical outcome.
CONCLUSION: Over the course of two years, surveillance in
which cystoscopy is partly replaced by current MA does not
provide a cost-effective alternative to the conventional surveil-
lance. The search for a surveillance test, combining similar or
better diagnostic accuracy than cystoscopy with lower patient
burden, needs to be continued.
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